Comparative evaluation of the degree of pegylation of poly(lactic-co-glycolic acid) nanoparticles in enhancing central nervous system delivery of loperamide
- PMID: 24028614
- DOI: 10.1111/jphp.12125
Comparative evaluation of the degree of pegylation of poly(lactic-co-glycolic acid) nanoparticles in enhancing central nervous system delivery of loperamide
Abstract
Objectives: In this study, we examined the relative cellular uptake of nanoparticles (NPs) formulated using poly(lactic-co-glycolic acid) (PLGA) polymers with increasing degree of pegylation (PLGA-PEG) and their potential to deliver loperamide to the brain of a mouse.
Method: NPs containing coumarin-6 or loperamide HCl were formulated using PLGA and PLGA-PEG, with PEG content of 5-15%, by the solvent evaporation method. NPs were characterised for size, surface charge, morphology, encapsulation efficiency and drug release. Cellular uptake of coumarin-6 NPs was examined in Caco-2 monolayers using confocal microscopy and central nervous system (CNS) delivery of loperamide HCl from the NPs was examined following intranasal administration in a mouse model.
Key findings: No difference in NP characteristics was observed, irrespective of degree of pegylation, except for the surface charge which increased with increasing PEG content. PLGA-PEG NPs were found to have increased cellular uptake in comparison to PLGA NPs. Interestingly, this pattern was reflected in the CNS delivery of loperamide HCl in the mouse model.
Conclusion: The results from this study show that PLGA-PEG NPs have the potential to act as carriers for the noninvasive administration of therapeutic agents to the brain and possibly across other physiological barriers.
Keywords: CNS; biodegradable polymers; blood brain barrier; nanoparticles; pegylated PLGA.
© 2013 Royal Pharmaceutical Society.
Similar articles
-
Intranasal and intravenous administration of octa-arginine modified poly(lactic-co-glycolic acid) nanoparticles facilitates central nervous system delivery of loperamide.J Pharm Pharmacol. 2015 Apr;67(4):525-36. doi: 10.1111/jphp.12347. Epub 2014 Dec 17. J Pharm Pharmacol. 2015. PMID: 25515568
-
Effects of surface modification of PLGA-PEG-PLGA nanoparticles on loperamide delivery efficiency across the blood-brain barrier.J Biomater Appl. 2013 Mar;27(7):909-22. doi: 10.1177/0885328211429495. Epub 2011 Dec 29. J Biomater Appl. 2013. PMID: 22207601
-
Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.Biomaterials. 2009 Jul;30(19):3297-306. doi: 10.1016/j.biomaterials.2009.02.045. Epub 2009 Mar 19. Biomaterials. 2009. PMID: 19299012
-
The effect of nanoparticle properties, detection method, delivery route and animal model on poly(lactic-co-glycolic) acid nanoparticles biodistribution in mice and rats.Drug Metab Rev. 2014 May;46(2):128-41. doi: 10.3109/03602532.2013.864664. Epub 2013 Dec 5. Drug Metab Rev. 2014. PMID: 24303927 Review.
-
Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier.Curr Med Chem. 2013;20(17):2212-25. doi: 10.2174/0929867311320170006. Curr Med Chem. 2013. PMID: 23458620 Review.
Cited by
-
Nanoparticles and the blood-brain barrier: advancing from in-vitro models towards therapeutic significance.Pharm Res. 2015 Apr;32(4):1161-85. doi: 10.1007/s11095-014-1545-6. Epub 2014 Dec 2. Pharm Res. 2015. PMID: 25446769 Review.
-
Effect of Size and Concentration of PLGA-PEG Nanoparticles on Activation and Aggregation of Washed Human Platelets.Pharmaceutics. 2019 Oct 4;11(10):514. doi: 10.3390/pharmaceutics11100514. Pharmaceutics. 2019. PMID: 31590303 Free PMC article.
-
Optimising PLGA-PEG Nanoparticle Size and Distribution for Enhanced Drug Targeting to the Inflamed Intestinal Barrier.Pharmaceutics. 2020 Nov 19;12(11):1114. doi: 10.3390/pharmaceutics12111114. Pharmaceutics. 2020. PMID: 33228175 Free PMC article.
-
Single-Emulsion P(HB-HV) Microsphere Preparation Tuned by Copolymer Molar Mass and Additive Interaction.ACS Omega. 2019 May 3;4(5):8122-8135. doi: 10.1021/acsomega.9b00824. eCollection 2019 May 31. ACS Omega. 2019. PMID: 31459903 Free PMC article.
-
Epilepsy Disease and Nose-to-Brain Delivery of Polymeric Nanoparticles: An Overview.Pharmaceutics. 2019 Mar 13;11(3):118. doi: 10.3390/pharmaceutics11030118. Pharmaceutics. 2019. PMID: 30871237 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous